AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9026952 — intervention group
Group type: EXPERIMENTAL
Intervention: Depakin syrup (initial dose 300 mg/day, increased to 1200 mg/day)
Number of subjects: 11
Study 1788755 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ng PGE 1/kg body weight/min and 15,000 i.U. of heparine continuously
Number of subjects: 133
Study 1788755 — intervention group
Group type: COMPARATOR
Intervention: 15,000 i.U. of heparine and 3 x 0.5 g of Aspirin
Number of subjects: 133
Study 1788755 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 micrograms PGE 1 in 250 ml saline twice daily
Number of subjects: 133
Study 1788755 — intervention group
Group type: COMPARATOR
Intervention: 250 ml saline twice over a period of three weeks
Number of subjects: 133
Study 7212227 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 0.4%, nitrous oxide 33%, oxygen 66%
Number of subjects: 20
Study 7212227 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide and oxygen ratio reversed for the first 3 minutes
Number of subjects: 20
Study 31069833 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (100 mJ/pulse; 15 Hz to hard tissue and 50 mJ/pulse; 30 Hz to soft tissue) plus SRP
Number of subjects: 27
Study 31069833 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 27
Study 30052229 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA (Group A)
Number of subjects: 50
Study 30052229 — intervention group
Group type: COMPARATOR
Intervention: ESP block (Group B)
Number of subjects: 50
Study 26876224 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha BRAIN®
Number of subjects: 63
Study 26876224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 25073836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% testosterone solution applied to the axilla
Number of subjects: 0
Study 25073836 — intervention group
Group type: COMPARATOR
Intervention: 1% testosterone solution applied to the inner arm
Number of subjects: 0
Study 22804703 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-based method
Number of subjects: 48
Study 22804703 — intervention group
Group type: COMPARATOR
Intervention: Picture-based method
Number of subjects: 48
Study 21178926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibration exercise (LFT, 20 Hz, 0.4 mm)
Number of subjects: 20
Study 21178926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration exercise (HFT, 36 Hz, 0.4 mm)
Number of subjects: 20
Study 21178926 — intervention group
Group type: COMPARATOR
Intervention: Non-vibration control (CON, 0 Hz, 0 mm)
Number of subjects: 20
Study 21178926 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (CON, LFT, HFT)
Number of subjects: 20
Study 17419744 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 0
Study 17419744 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 0
Study 15744462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study 15744462 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12466506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control therapy
Number of subjects: 4060
Study 12466506 — intervention group
Group type: COMPARATOR
Intervention: Rate-control therapy
Number of subjects: 4060
Study 10329827 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injections (placebo)
Number of subjects: 132
Study 10329827 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected allergens (active substances)
Number of subjects: 132
Study 7552560 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment teams
Number of subjects: 0
Study 7552560 — intervention group
Group type: COMPARATOR
Intervention: Standard case management programs
Number of subjects: 0
Study 2117202 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (including recombinant t-PA and urokinase)
Number of subjects: 100000
Study 2117202 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant t-PA infusions
Number of subjects: 100000
Study 2117202 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative administration regimens of urokinase
Number of subjects: 100000
Study 2117202 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 100000
Study 7388323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose heparin (1000 units/1000 ml infusate) given intravenously
Number of subjects: 108
Study 7388323 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low dose heparin (5000 units 8-hourly)
Number of subjects: 108
Study 30903598 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepted participation in clinical trial
Number of subjects: 16
Study 30903598 — intervention group
Group type: COMPARATOR
Intervention: Refused participation in clinical trial
Number of subjects: 16
Study 31798841 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-identified change agents (PICAs)
Number of subjects: 0
Study 31798841 — intervention group
Group type: EXPERIMENTAL
Intervention: Management-selected change agents (MSCAs)
Number of subjects: 0
Study 31798841 — intervention group
Group type: COMPARATOR
Intervention: Both PICAs and MSCAs
Number of subjects: 0
Study 31798841 — intervention group
Group type: EXPERIMENTAL
Intervention: PICAs
Number of subjects: 0
Study 31798841 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCAs
Number of subjects: 0
Study 27284082 — intervention group
Group type: EXPERIMENTAL
Intervention: Active dose of methylene blue (195 mg)
Number of subjects: 37
Study 27284082 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 mg)
Number of subjects: 37
Study 25858972 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified care training (n=67)
Number of subjects: 100
Study 25858972 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=33)
Number of subjects: 100
Study 24352096 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplement with nutritional doses of antioxidant nutrients and phytochemicals (MP) for eight weeks
Number of subjects: 80
Study 24352096 — intervention group
Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 80
Study 21401336 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio® tape (KT) and physiotherapy
Number of subjects: 31
Study 21401336 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 31
Study 19585317 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g L‐citrulline‐malate
Number of subjects: 17
Study 19585317 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 17453233 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezing a rubber ring at 30% of Maximal Voluntary Contraction (MVC) for 6 weeks
Number of subjects: 14
Study 11000589 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (patients with left ventricular thrombus)
Number of subjects: 80
Study 11000589 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (patients without left ventricular thrombus)
Number of subjects: 80
Study 8638790 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 micrograms/kg)
Number of subjects: 26
Study 8638790 — intervention group
Group type: COMPARATOR
Intervention: Control (no clonidine)
Number of subjects: 26
Study 1992957 — intervention group
Group type: EXPERIMENTAL
Intervention: Filicol (9 g/d)
Number of subjects: 50
Study 1992957 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (1.2 g/d)
Number of subjects: 50
Study 6391497 — intervention group
Group type: EXPERIMENTAL
Intervention: pizotifen 1 mg
Number of subjects: 6
Study 6391497 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg
Number of subjects: 6
Study 6391497 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 30851515 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + SIN (Methotrexate + Sinomenine) at a dose of 120 mg twice daily
Number of subjects: 120
Study 30851515 — intervention group
Group type: COMPARATOR
Intervention: MTX + LEF (Methotrexate + Leflunomide) at a dose of 20 mg once daily
Number of subjects: 120
Study 30851515 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + SIN
Number of subjects: 120
Study 30851515 — intervention group
Group type: COMPARATOR
Intervention: MTX + LEF
Number of subjects: 120
Study 30890061 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue ART after delivery
Number of subjects: 1611
Study 30890061 — intervention group
Group type: COMPARATOR
Intervention: Discontinue ART after delivery
Number of subjects: 1611
Study 26503762 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (12 IU morning and night, 24 IU per day for 5 weeks)
Number of subjects: 31
Study 26503762 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 31
Study 25306681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2-1.4 mcg/kg/hour)
Number of subjects: 60
Study 25306681 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5 mg 3 times a day intramuscularly and 0.1 mg/kg intravenously)
Number of subjects: 60
Study 25306681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 25306681 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol with benzodiazepines
Number of subjects: 60
Study 22858869 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized high-intensity rehabilitation programme (n = 43)
Number of subjects: 85
Study 22858869 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group, n = 42)
Number of subjects: 85
Study 20123246 — intervention group
Group type: EXPERIMENTAL
Intervention: AFT plus medical therapy
Number of subjects: 168
Study 20123246 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 168
Study 17599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 U/kg)
Number of subjects: 81
Study 17599852 — intervention group
Group type: COMPARATOR
Intervention: Sliding scale regular insulin (SSRI)
Number of subjects: 81
Study 17599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion in ICU
Number of subjects: 81
Study 17599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ICU patients treated directly with insulin glargine
Number of subjects: 81
Study 17599852 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall blood glucose measurements
Number of subjects: 81
Study 15678342 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA (0.1 mmol/kg)
Number of subjects: 63
Study 15678342 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA (0.1 mmol/kg)
Number of subjects: 63
Study 11879247 — intervention group
Group type: COMPARATOR
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 12
Study 11879247 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 12
Study 11879247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both online HDF and AFB
Number of subjects: 12
Study 11879247 — intervention group
Group type: COMPARATOR
Intervention: All 3 treatments
Number of subjects: 12
Study 10094106 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (n = 19)
Number of subjects: 36
Study 10094106 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (n = 17)
Number of subjects: 36
Study 7539121 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention (HI) group (n = 64)
Number of subjects: 130
Study 7539121 — intervention group
Group type: COMPARATOR
Intervention: Clinic only group (C) (n = 66)
Number of subjects: 130
Study 7539121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 130
Study 2186220 — intervention group
Group type: EXPERIMENTAL
Intervention: Phthivazide 0.5 g three times a day for 15-20 days
Number of subjects: 540
Study 2186220 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 540
Study 30573719 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen trometamol + 8 mg thiocolchicoside
Number of subjects: 75
Study 30573719 — intervention group
Group type: COMPARATOR
Intervention: 25 mg dexketoprofen trometamol
Number of subjects: 75
Study 30573719 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen trometamol + 4 mg thiocolchicoside
Number of subjects: 75
Study 26661716 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP sensors placed on the forehead
Number of subjects: 30
Study 26661716 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP sensors placed on the nose
Number of subjects: 30
Study 26661716 — intervention group
Group type: EXPERIMENTAL
Intervention: AEP sensors placed on the mandible
Number of subjects: 30
Study 25923482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine-rich whey protein isolate (Immunocal®) 20 g/day
Number of subjects: 99
Study 25923482 — intervention group
Group type: COMPARATOR
Intervention: Casein 20 g/day
Number of subjects: 99
Study 23292204 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 21051764 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit Training Physical Therapy (CTPT)
Number of subjects: 180
Study 21051764 — intervention group
Group type: COMPARATOR
Intervention: Standard Physical Therapy (SPT)
Number of subjects: 180
Study 18580816 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 0
Study 18580816 — intervention group
Group type: COMPARATOR
Intervention: Sham electroconvulsive therapy (sham ECT)
Number of subjects: 0
Study 17722971 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600mg four times daily in addition to usual asthma care
Number of subjects: 2458
Study 17722971 — intervention group
Group type: COMPARATOR
Intervention: Usual asthma care only
Number of subjects: 2458
Study 16739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 100
Study 16739360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12118641 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment during labour
Number of subjects: 90
Study 12118641 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (Control)
Number of subjects: 90
Study 9832074 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANS diet (trans fatty acid‐enriched diet)
Number of subjects: 14
Study 9832074 — intervention group
Group type: EXPERIMENTAL
Intervention: OLEIC diet (oleic acid‐enriched diet)
Number of subjects: 14
Study 8127888 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (0.1‐10 mg, orally)
Number of subjects: 20
Study 8127888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2672732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic evidence of a large amount of gastric fluid (greater than or equal to 5 cm2)
Number of subjects: 143
Study 2672732 — intervention group
Group type: COMPARATOR
Intervention: Sonographic evidence of little or no fluid (less than 5 cm2)
Number of subjects: 143
Study 2672732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic evidence of a large amount of gastric fluid
Number of subjects: 143
Study 324400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg every 12 h for 5 days)
Number of subjects: 89
Study 324400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 324400 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 89
Study 29961342 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation group (coronary artery disease smokers)
Number of subjects: 58
Study 29961342 — intervention group
Group type: COMPARATOR
Intervention: Continuous smoking group (coronary artery disease smokers)
Number of subjects: 58
Study 29961342 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-smokers (baseline control)
Number of subjects: 58
Study 27885840 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine
Number of subjects: 0
Study 27885840 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 25947184 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter therapy (5 times a week for 2 weeks)
Number of subjects: 64
Study 24334198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexunzipped website for sexual health
Number of subjects: 22
Study 24334198 — intervention group
Group type: COMPARATOR
Intervention: Information-only website
Number of subjects: 22
Study 21262066 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg of iodide (KI)
Number of subjects: 30
Study 21262066 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg of iodide (KI)
Number of subjects: 30
Study 21262066 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg of iodide (KI)
Number of subjects: 30
Study 21262066 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide supplement (100-300 μg/d)
Number of subjects: 30
Study 19228612 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1800
Study 19228612 — intervention group
Group type: COMPARATOR
Intervention: Coronary-artery bypass grafting (CABG)
Number of subjects: 1800
Study 19228612 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1800
Study 19228612 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1800
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Statements consistent with a male
Number of subjects: 0
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Statements traditionally associated with a female
Number of subjects: 0
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that the speaker was a gay male or a lesbian female
Number of subjects: 0
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention during test
Number of subjects: 0
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of the detrimental impact of stereotypes
Number of subjects: 0
Study 16484106 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral statements
Number of subjects: 0
Study 12616665 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) alone or in combination with didanosine
Number of subjects: 394
Study 10851205 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with reduced-dose thrombolysis (alteplase or reteplase)
Number of subjects: 51
Study 10851205 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no AMI)
Number of subjects: 51
Study 10851205 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AMI
Number of subjects: 51
Study 9089002 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini 30 (0.03 mg levonorgestrel)
Number of subjects: 24
Study 9089002 — intervention group
Group type: COMPARATOR
Intervention: Microval (reference)
Number of subjects: 24
Study 7903578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive therapy
Number of subjects: 1627
Study 7903578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study 3009962 — intervention group
Group type: EXPERIMENTAL
Intervention: nabilone (2 X 2 mg/day)
Number of subjects: 20
Study 3009962 — intervention group
Group type: COMPARATOR
Intervention: alizapride (3 X 150 mg/day)
Number of subjects: 20
Study 30573493 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐SEE Steps (Incredible Years Infant book and possible group-based programmes)
Number of subjects: 0
Study 30573493 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 0
Study 27171108 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% maltodextrin mouth rinse
Number of subjects: 9
Study 27171108 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin mouth rinse
Number of subjects: 9
Study 27171108 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% maltodextrin mouth rinse
Number of subjects: 9
Study 27171108 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 9
Study 23963800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean (Med) diet enriched in MUFA with virgin olive oil
Number of subjects: 20
Study 23963800 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PUFA diet (low-fat, high-carbohydrate diet enriched in n-3 PUFA)
Number of subjects: 20
Study 23963800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean (Med) diet
Number of subjects: 20
Study 23963800 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-PUFA diet
Number of subjects: 20
Study 23963800 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet
Number of subjects: 20
Study 23137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow cell (BMC) injection (100 × 10^6 BMC)
Number of subjects: 16
Study 23137509 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial bone marrow cell (BMC) injection
Number of subjects: 16
Study 23137509 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 16
Study 20347835 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 40
Study 20347835 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest)
Number of subjects: 40
Study 18564727 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum containing 10 mg CHX, used for 20 min twice daily
Number of subjects: 18
Study 18564727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15096806 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 85
Study 15096806 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) or Stavudine (d4T)
Number of subjects: 85
Study 15096806 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ABC vs ZDV/d4T
Number of subjects: 85
Study 15096806 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment analysis for ABC arm
Number of subjects: 85
Study 15096806 — intervention group
Group type: COMPARATOR
Intervention: Visceral fat accumulation, buffalo hump, self-assessed lipodystrophy, LCDS
Number of subjects: 85
Study 12219064 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 at 1 g/kg per day
Number of subjects: 40
Study 12219064 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 at 1.5 g/kg per day
Number of subjects: 40
Study 12219064 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 3350 at 0.25 g/kg per day
Number of subjects: 40